Gene
LPAR3
| Entrez Gene ID | 23566 (See on NCBI) |
| Description | lysophosphatidic acid receptor 3 |
| Gene Synonyms | EDG7, Edg-7, GPCR, HOFNH30, LP-A3, LPA3, RP4-678I3 |
| Node consisting of this Gene | LPAR3 EDG7 |
Networks including this gene
| GSE10063_top8000 - GSE10063 - SiGN-BN NNSR | Effects of tobacco smoke on gene expression and cellular pathways in a cellular model of oral leukoplakia |
| GSE10245_top8000 - GSE10245 - SiGN-BN NNSR | Gene expression differences between adenocarcinoma and squamous cell carcinoma in human NSCLC |
| GSE10843_top8000 - GSE10843 - SiGN-BN NNSR | mRNA Cancer Cell Line Profiles |
| GSE10890_top8000 - GSE10890 - SiGN-BN NNSR | mRNA Breast Cancer Cell Line Profiles |
| GSE10972_top8000 - GSE10972 - SiGN-BN NNSR | Colon cancer |
| GSE11582_top8000 - GSE11582 - SiGN-BN NNSR | Genetic Analysis of Human Traits In-Vitro: Drug Response and Gene Expression in Lymphoblastoid Cell Lines |
| GSE11729_top8000 - GSE11729 - SiGN-BN NNSR | H1299 EGF and Iressa stimulation |
| GSE12195_top8000 - GSE12195 - SiGN-BN NNSR | Mutations of multiple genes deregulate the NF-kB pathway in diffuse large B cell lymphoma |
| GSE12276_top8000 - GSE12276 - SiGN-BN NNSR | Expression data from primary breast tumors |
| GSE12391_top8000 - GSE12391 - SiGN-BN NNSR | Melanoma: comparison between common nevi, radial/vertical growth phase melanoma, metastases and dysplastic nevi |
| GSE12470_top8000 - GSE12470 - SiGN-BN NNSR | Gene expression profiles of serous ovarian cancer samples |
| GSE12622_top8000 - GSE12622 - SiGN-BN NNSR | Tumor-associated stroma derived from primary clinical breast cancer samples (II) |
| GSE12667_top8000 - GSE12667 - SiGN-BN NNSR | Discovery of somatic mutations in lung adenocarcinomas |
| GSE13009_top8000 - GSE13009 - SiGN-BN NNSR | MCF7 EGF, HRG stimulation |
| GSE13507_top8000 - GSE13507 - SiGN-BN NNSR | Predective Value of Prognosis-Related Gene Expression Study in Primary Bladder Cancer |
| GSE13598_top8000 - GSE13598 - SiGN-BN NNSR | mRNA expression of 131 cancer cell lines |
| GSE14206_top8000 - GSE14206 - SiGN-BN NNSR | Analysis of ETS gene expression patterns uncovers novel ETS mediated gene silencing pathways in prostate cancers |
| GSE14764_top8000 - GSE14764 - SiGN-BN NNSR | A Prognostic Gene Expression Index in Ovarian Cancer |
| GSE14814_top8000 - GSE14814 - SiGN-BN NNSR | Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer |
| GSE15212_top8000 - GSE15212 - SiGN-BN NNSR | Identification and validation of NOL5A and RPS2 as potential therapeutic targtes in colorectal cancer |
| GSE15395_top8000 - GSE15395 - SiGN-BN NNSR | HCT116 tumor cells treated with a CDK inhibitor |
| GSE15396_top8000 - GSE15396 - SiGN-BN NNSR | Peripheral blood mononuclear, DU145, and HCT116 cells treated with a CDK inhibitor |
| GSE15471_top8000 - GSE15471 - SiGN-BN NNSR | Whole-Tissue Gene Expression Study of Pancreatic Ductal Adenocarcinoma |
| GSE15966_top8000 - GSE15966 - SiGN-BN NNSR | Gene expression signature predictive of rapid response to imatinib mesylate in Gastrointestinal Stromal Tumor (GIST) |
| GSE16120_top8000 - GSE16120 - SiGN-BN NNSR | Gene profiling, mutations and expression of epidermal growth factor receptor in androgen-dependent prostate cancer |
| GSE16237_top8000 - GSE16237 - SiGN-BN NNSR | Expression data of human neuroblastoma tissue samples |
| GSE16446_top8000 - GSE16446 - SiGN-BN NNSR | Predicting the efficacy of anthracyclines in breast cancer (BC) patients: The results of the TOP trial |
| GSE16515_top8000 - GSE16515 - SiGN-BN NNSR | Expression data from Mayo Clinic Pancreatic Tumor and Normal samples |
| GSE16581_top8000 - GSE16581 - SiGN-BN NNSR | Genomic landscape of meningiomas: gene expression |
| GSE16987_top8000 - GSE16987 - SiGN-BN NNSR | A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis |
| GSE17913_top8000 - GSE17913 - SiGN-BN NNSR | Effects of Cigarette Smoke on the Human Oral Mucosal Transcriptome |
| GSE17951_top8000 - GSE17951 - SiGN-BN NNSR | Gene expression analysis of prostate cancer samples using Affymetrix U133Plus2 array |
| GSE18520_top8000 - GSE18520 - SiGN-BN NNSR | Whole-genome oligonucleotide expression analysis of papillary serous ovarian adenocarcinomas |
| GSE18521_top8000 - GSE18521 - SiGN-BN NNSR | A gene signature predictive for outcome in advanced ovarian cancer identifies a novel survival factor: MAGP2 |
| GSE18684_top8000 - GSE18684 - SiGN-BN NNSR | Fine mapping of androgen regulated genes in LNCaP cells |
| GSE18842_top8000 - GSE18842 - SiGN-BN NNSR | Gene expression analysis of human lung cancer and control samples |
| GSE19027_top8000 - GSE19027 - SiGN-BN NNSR | Antioxidant response gene expression in the bronchial airway epithelial cells of smokers at risk for lung cancer |
| GSE19494_top8000 - GSE19494 - SiGN-BN NNSR | Subcutaneous adipose tissue (SAT) gene expression patterns between weight control and regaining weight subjects |
| GSE20189_top8000 - GSE20189 - SiGN-BN NNSR | A gene expression signature from peripheral whole blood for stage I lung adenocarcinoma |
| GSE20685_top8000 - GSE20685 - SiGN-BN NNSR | Microarray-based molecular subtyping of breast cancer |
| GSE20842_top8000 - GSE20842 - SiGN-BN NNSR | Mutated KRAS induces overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas |
| GSE21501_top8000 - GSE21501 - SiGN-BN NNSR | A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma |
| GSE22153_top8000 - GSE22153 - SiGN-BN NNSR | Gene Experssion Profiling-Based Identification of Molecular Subtypes in Stage IV Melanoma with Different Clinical Outcome (test set) |
| GSE22597_top8000 - GSE22597 - SiGN-BN NNSR | Expression data from Fine Needle Aspiration (FNA) biopsies from breast cancer patients |
| GSE2294_top8000 - GSE2294 - SiGN-BN NNSR | A Modular Analysis of Breast Cancer Reveals a Novel Low-Grade Molecular Signature in Estrogen Receptor-Positive Tumors |
| GSE23036_top8000 - GSE23036 - SiGN-BN NNSR | Gene expression signatures and molecular markers associated with clinical outcome in locally advanced head and neck carcinoma |
| GSE23553_top8000 - GSE23553 - SiGN-BN NNSR | Gene expression changes with induction of in-vitro platinum-resistance in ovarian cancer cell lines. |
| GSE23593_top8000 - GSE23593 - SiGN-BN NNSR | Intratumor Heterogeneity and Precision of Microarray-Based Predictors of Breast Cancer Biology and Clinical Outcome |
| GSE23991_top8000 - GSE23991 - SiGN-BN NNSR | Effect of zebularine on primary human liver cancer cell lines |
| GSE24124_top8000 - GSE24124 - SiGN-BN NNSR | Major gene partners of a favorable biomarker in ER(+) breast cancer |
| GSE25136_top8000 - GSE25136 - SiGN-BN NNSR | Optimizing molecular signatures for prostate cancer recurrence |
| GSE25428_top8000 - GSE25428 - SiGN-BN NNSR | Gene expression profiles of ovarian cancer cell lines in the presence and absence of a DNA methyltransferase inhibitor |
| GSE2603_top8000 - GSE2603 - SiGN-BN NNSR | Subpopulations of MDA-MB-231 and Primary Breast Cancers |
| GSE26549_top8000 - GSE26549 - SiGN-BN NNSR | Gene Expression Profiling Predicts the Development of Oral Cancer |
| GSE26639_top8000 - GSE26639 - SiGN-BN NNSR | Expression Data from 226 patients of the REMAGUS02 trial |
| GSE26712_top8000 - GSE26712 - SiGN-BN NNSR | A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer |
| GSE28497_top8000 - GSE28497 - SiGN-BN NNSR | New markers for minimal residual disease detection in acute lymphoblastic leukemia |
| GSE29288_top8000 - GSE29288 - SiGN-BN NNSR | Comparison between cell lines from 9 different cancer tissue (NCI-60) (Agilent WG platform) |
| GSE29598_top8000 - GSE29598 - SiGN-BN NNSR | A Methodology for Utilization of Predictive Genomic Signatures in FFPE Samples |
| GSE29817_top8000 - GSE29817 - SiGN-BN NNSR | Membranous Expression of Ectodomain Isoforms of the Epidermal Growth Factor Receptor (EGFR) Predicts Outcome after Chemoradiotherapy of Lymph Node Negative Cervical Cancer |
| GSE30375_top8000 - GSE30375 - SiGN-BN NNSR | Gene expression data from sorted and unsorted primary human acute myeloid leukemia (AML) samples |
| GSE30784_top8000 - GSE30784 - SiGN-BN NNSR | Gene expression profiling of oral squamous cell carcinoma (OSCC) |
| GSE3149_top8000 - GSE3149 - SiGN-BN NNSR | Ovarian Cancer Dataset |
| GSE31519_top8000 - GSE31519 - SiGN-BN NNSR | A Clinically Relevant Gene Signature in Triple-Negative and Basal-Like Breast Cancer |
| GSE31552_top8000 - GSE31552 - SiGN-BN NNSR | Expression Data from human Lung tissue of Patients with Non Small Cell Lung Cancer (NSCLC) |
| GSE3167_top8000 - GSE3167 - SiGN-BN NNSR | Classification of carcinoma in situ lesions in human bladder cancer |
| GSE32269_top8000 - GSE32269 - SiGN-BN NNSR | Expression data for primary localized prostate cancer versus castration-resistant bone metastatic prostate cancer |
| GSE3593_top8000 - GSE3593 - SiGN-BN NNSR | Genomic approach to refine prognosis for adjuvant therapy in early stage non-small cell lung carcinoma |
| GSE3726_top8000 - GSE3726 - SiGN-BN NNSR | Prognostic gene signatures can be measured with samples stored in RNAlater |
| GSE4115_top8000 - GSE4115 - SiGN-BN NNSR | Airway Epithelial Gene Expression Diagnostic for the Evaluation of Smokers with Suspect Lung Cancer |
| GSE4122_top8000 - GSE4122 - SiGN-BN NNSR | Gene Expression Analysis of Ovarian Samples |
| GSE4573_top8000 - GSE4573 - SiGN-BN NNSR | Gene expression signatures for predicting prognosis of squamous cell lung carcinomas |
| GSE4823_top8000 - GSE4823 - SiGN-BN NNSR | Comparison of normal breast epithelium and stroma from reduction and I.D.C. cases |
| GSE5851_top8000 - GSE5851 - SiGN-BN NNSR | Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC |
| GSE6008_top8000 - GSE6008 - SiGN-BN NNSR | Human ovarian tumors and normal ovaries |
| GSE6462_top8000 - GSE6462 - SiGN-BN NNSR | MCF7 dose response |
| GSE6481_top8000 - GSE6481 - SiGN-BN NNSR | Gene Expression Analysis of Soft Tissue Sarcomas: Characterization & Reclassification of Malignant Fibrous Histiocytoma |
| GSE6956_top8000 - GSE6956 - SiGN-BN NNSR | Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men |
| GSE7390_top8000 - GSE7390 - SiGN-BN NNSR | Strong Time Dependence of the 76-Gene Prognostic Signature |
| GSE7604_top8000 - GSE7604 - SiGN-BN NNSR | Human Colon tumor vs Normal Human DNA |
| GSE7606_top8000 - GSE7606 - SiGN-BN NNSR | Human Melanoma vs Normal Human DNA |
| GSE8218_top8000 - GSE8218 - SiGN-BN NNSR | Gene expression data from prostate cancer samples |
| GSE8835_top8000 - GSE8835 - SiGN-BN NNSR | Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. |
| GSE8894_top8000 - GSE8894 - SiGN-BN NNSR | Prediction of Recurrence-Free Survival in Postoperative NSCLC Patients—a Useful Prospective Clinical Practice |
| GSE9014_top8000 - GSE9014 - SiGN-BN NNSR | Tumor-associated stroma derived from primary clinical breast cancer samples |
| GSE9169_top8000 - GSE9169 - SiGN-BN NNSR | Gene expression during neuronal differentiation in two subtypes of SH-SY5Y |
| GSE9309_top8000 - GSE9309 - SiGN-BN NNSR | Recovery of biological information under heterogeneous experimental conditions using subgroup standardization. |
(87 networks)
